Christopher Obrien,James Zangrilli,Tushar Shah,Guy Brusselle
申请号：
US15783289
公开号：
US20180030131A1
申请日:
2017.10.13
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising administering a therapeutically effective dose of reslizumab to the patient whose symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/μL.
